Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Voretigene Neparvovec

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche writes off $3B on lower sales forecasts for gene therapies, cancer drugs
    Roche writes off $3B on lower sales forecasts for gene therapies, cancer drugs

    03 Feb 2023

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/roche-impairment-write-down-spark-gene-therapy/641939/

    BIOPHARMADIVE
    03 Feb 2023
    Share Share
    Novartis and the (pCPA) conclude negotiations for Luxturna
    Novartis and the (pCPA) conclude negotiations for Luxturna

    20 Sep 2022

    // NEWSWIRE

    https://www.newswire.ca/news-releases/novartis-and-the-pan-canadian-pharmaceutical-alliance-pcpa-conclude-negotiations-for-luxturna-r-a-gene-therapy-for-previously-untreatable-inherited-vision-loss-1--803517945.html

    NEWSWIRE
    20 Sep 2022
    Share Share
    In vivo gene editing grabs the spotlight after Intellia triumph
    In vivo gene editing grabs the spotlight after Intellia triumph

    29 Sep 2021

    // Arlene Weintraub FIERCEBIOTECH

    https://www.fiercebiotech.com/research/vivo-gene-editing-grabs-spotlight-after-intellia-triumph-but-challenges-loom

    Arlene Weintraub FIERCEBIOTECH
    29 Sep 2021
    Share Share
    Luxturna inventor launches new gene therapy biotech with $19M
    Luxturna inventor launches new gene therapy biotech with $19M

    23 Sep 2021

    // Kyle LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/luxturna-inventor-behind-new-eye-gene-therapy-biotech-opus-genetics-snags-19m

    Kyle LaHucik FIERCEBIOTECH
    23 Sep 2021
    Share Share
    Horama refuels with a Series B expansion and a new name
    Horama refuels with a Series B expansion and a new name

    20 Jul 2021

    // Nicole DeFeudis ENDPTS

    https://endpts.com/2-am-on-a-mission-to-treat-patients-not-covered-by-luxturna-horama-refuels-with-a-series-b-expansion-and-a-new-name/

    Nicole DeFeudis ENDPTS
    20 Jul 2021
    Share Share
    First patient undergoes Luxturna gene therapy on NHS
    First patient undergoes Luxturna gene therapy on NHS

    18 Feb 2020

    // Anna Smith PHARMATIMES

    http://www.pharmatimes.com/news/first_patient_undergoes_luxturna_gene_therapy_on_nhs_1326391

    Anna Smith PHARMATIMES
    18 Feb 2020
    Share Share